Dimension Therapeutics has filed an S-1 form with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO). No terms were given in the filing, but the offering is valued up to $115 million. The company intends to file on the Nasdaq Global Market under the symbol DMTX.

The underwriters for the offering are Goldman Sachs, Citigroup, Wells Fargo, Canaccord Genuity and Cantor Fitzgerald.

This is a leading gene therapy platform company focused on discovering and developing new therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. Its initial programs address hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency and glycogen storage disease type Ia (GSDIa).

In August 2015, the company submitted an Investigational New Drug application (IND) with the U.S. Food and Drug Administration (FDA) for the lead product candidate, DTX101, for the treatment of hemophilia B. In September 2015, Dimension received notification allowing it to proceed with Phase 1/2 clinical trial of DTX101. DTX101 was also granted Orphan Drug Designation in the United States in August 2015 and Fast Track Designation in September 2015 for the treatment of hemophilia B. The company plans to initiate clinical trials for DTX101 by the end of 2015.

ALSO READ: Jefferies Starts Coverage on Biotechs: 3 Top Stocks to Buy Now

In the filing Dimension said:

We have developed a robust scientific platform that brings together deep expertise in rare genetic diseases, liver biology, adeno-associated virus, or AAV, gene therapy and vector manufacturing. We believe that by leveraging the expertise created by our platform we will be able to accelerate the research and development of our pipeline of programs while continuing to discover and develop the next generation of products in this field. We have made and continue to make significant investments in order to develop manufacturing processes designed to reliably produce high quality AAV vectors at commercial scale. We believe that our manufacturing processes, methods and expertise will ultimately give us the most comprehensive manufacturing platform developed to date for AAV-based gene therapy product candidates.

The company intends to use the net proceeds from this offering to further develop its pipeline, while using the remainder for working capital and other general corporate purposes.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.